Understand the source comparison
Quantitative Comparison: Ipamorelin Versus First-Generation GHRPs
The case for ipamorelin selective GH secretion becomes clearest when you compare hormone panel results across secretagogues at doses producing equivalent GH release. A 2006 randomized crossover trial published in the Journal of Clinical Endocrinology and Metab
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The case for ipamorelin selective GH secretion becomes clearest when you compare hormone panel results across secretagogues at doses producing equivalent GH release. A 2006 randomized crossover trial published in the Journal of Clinical Endocrinology and Metabolism tested ipamorelin, GHRP-2, GHRP-6, and hexarelin at doses calibrated to produce comparable GH peaks (approximately 10–12 ng/mL). All four compounds achieved the target GH response. The difference was everything else.
- GHRP-6 elevated cortisol by 47% above baseline, prolactin by 68%, and ACTH by 35%. Hexarelin—the most potent first-generation compound—produced the largest GH pulse (15.2 ng/mL) but also the worst off-target profile: cortisol up 62%, prolactin up 110%, ACTH up 48%. GHRP-2 sat in the middle: GH response comparable to ipamorelin, but cortisol elevation of 28% and prolactin increase of 41%. Ipamorelin? GH peaked at 11.4 ng/mL with cortisol change of +3% (not statistically significant) and prolactin change of +2% (also non-significant).
- Those percentages translate to real experimental problems. Elevated cortisol is catabolic—it breaks down muscle protein, mobilizes amino acids for gluconeogenesis, and opposes anabolic signaling pathways that GH is supposed to activate. If you're studying GH's effect on lean mass accretion or nitrogen retention, a concurrent 40% cortisol spike contaminates the result. Prolactin elevation suppresses gonadotropin-releasing hormone (GnRH), which reduces LH and FSH secretion and downstream testosterone production in males—again, a confounding variable if your research involves androgens, libido, or reproductive tissue. ACTH stimulates the adrenal cortex to produce more cortisol, amplifying the catabolic problem.
- Ipamorelin selective GH secretion removes these confounders. What you measure after ipamorelin administration is attributable to growth hormone's direct effects—not cortisol's opposing catabolic signal, not prolactin's gonadal suppression, not ACTH-mediated adrenal stimulation. That's why every major GH pulse study published after 2008 uses either ipamorelin or CJC-1295 (a GHRH analog) as the reference compound—they produce clean data.